MPD: All measures mapped to paradigm code 'basetrt'

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Albers1:1	Albers1	lipid profile	high-fat diet	total cholesterol (plasma CHOL) [mmol/L] chol 1901 baseline after 6wks on diet Δchange	inbred	15	both	6-8wks	N=8	1999

Albers1:2	Albers1	lipid profile	high-fat diet	HDL cholesterol (plasma HDL) [mmol/L] HDLC 1902 baseline after 6wks on diet Δchange	inbred	15	both	6-8wks	N=8	1999

Albers1:3	Albers1	lipid profile	high-fat diet	non-HDL cholesterol (plasma non-HDL) [mmol/L] nonHDLC 1903 baseline after 6wks on diet Δchange	inbred	15	both	6-8wks	N=8	1999

Albers1:10	Albers1	lipid profile	high-fat diet	total phospholipid (plasma) [mmol/L] PL 1910 baseline after 6wks on diet Δchange	inbred	15	both	6-8wks	N=8	1999

Albers1:11	Albers1	lipid profile	high-fat diet	HDL phospholipid (plasma) [mmol/L] PL_HDL 1911 baseline after 6wks on diet Δchange	inbred	15	both	6-8wks	N=8	1999

Albers1:12	Albers1	lipid profile	high-fat diet	non-HDL phospholipid (plasma) [mmol/L] PL_nonHDL 1912 baseline after 6wks on diet Δchange	inbred	15	both	6-8wks	N=8	1999

Albers1:13	Albers1	protein activity assessment	high-fat diet	phospholipid transfer protein activity (plasma) [µmol/mL/h] PLTP 1913 baseline after 6wks on diet Δchange	inbred	15	both	6-8wks	N=8	1999

Albers1:22	Albers1	lipid profile	high-fat diet	percentage of large HDL particles (10-13 nm) (plasma) [%] largeHDL 1922 baseline after 6wks on diet Δchange	inbred	15	both	6-8wks	N=8	1999

Albers1:23	Albers1	lipid profile	high-fat diet	HDL peak size (plasma) [nm] HDLsize 1923 baseline after 6wks on diet Δchange	inbred	15	both	6-8wks	N=8	1999

Albers1:28	Albers1	lipid profile	high-fat diet	triglycerides (plasma TG) (4h fast) [mmol/L] TG 1928 baseline after 6wks on diet Δchange	inbred	15	both	6-8wks	N=8	1999

Crabbe3:40	Crabbe3	rotarod	ethanol	latency to-fall, accelerating rotarod, test day 1 20 rpm/min (ARR1) [s] ARR1_20rpm 15840 baseline ethanol difference	inbred	8	both	9-17wks	N=6	2003

Crabbe3:45	Crabbe3	rotarod	ethanol	latency to-fall, accelerating rotarod, test day 2 30 rpm/min (ARR1) [s] ARR1_30rpm 15845 baseline ethanol difference	inbred	8	both	9-17wks	N=6	2003

Crabbe3:55	Crabbe3	rotarod	ethanol	latency to fall, accelerating rotarod, 20 rpm/min (ARR2) [s] ARR2_20rpm 15855 baseline ethanol	inbred	21	both	9-17wks	N=9	2003

Crabbe4:6	Crabbe4	grip strength	ethanol	grip strength test: peak force applied [g] grip 19106 baseline 30min after ethanol	inbred	21	both	7-12wks	N=6	2003

Gershenfeld1:3	Gershenfeld1	tail suspension test	imipramine	TST duration of immobility, treatment group, 6 min test [s] TST_Rx 16203 baseline imipramine 30mg/kg	inbred	12	m	5-10wks	N=5	2003

Mathes1:1	Mathes1	body weight	exercise	body weight [g] bw 45201 before exercise after exercise difference	CC pre w/par	184	m	10-12wks	N=1	2011

Mathes1:4	Mathes1	MRI	exercise	percent fat, whole body with head [%] pct_fat 45204 before exercise after exercise difference	CC pre w/par	184	m	10-12wks	N=1	2011

Mathes1:7	Mathes1	intake monitoring	exercise	caloric intake [kcal/d] calories 45207 before exercise during exercise	CC pre w/par	183	m	10-12wks	N=1	2011

Nadeau1:1	Nadeau1	body weight	high-fat diet	body weight [g] bw 28301 baseline after 12wks on diet Δchange	B6.A consomic w/par	24	m	5wks	N=18	2008

Nadeau2:1	Nadeau2	body size and weight	high-fat high-sucrose diet	body weight [g] bw 53001 baseline after 16wks on diet weight gain	B6.A consomic w/par	24	m	5wks	N=39	2015

Naggert1:2	Naggert1	metabolic panel	high-fat diet	glucose (plasma GLU, 4h fast) [mg/dL] GLU 14302 baseline after 17wks on diet Δchange	inbred w/CC7	43	both	7-9wks	N=10	2003

Paigen1:5	Paigen1	body weight	high-fat diet	body weight [g] bw 2905 start after 8wks on diet fold change	inbred	43	both	7-11wks	N=12	2000

Paigen2:4	Paigen2	lipid profile	high-fat diet	HDL cholesterol (plasma) [mg/dL] HDLC 9904 baseline after 17wks on diet Δchange	inbred w/CC7	42	both	7-9wks	N=9	2002

Paigen2:5	Paigen2	lipid profile	high-fat diet	non-HDL cholesterol (plasma) [mg/dL] nonHDL 9905 baseline after 17wks on diet Δchange	inbred w/CC7	42	both	7-9wks	N=9	2002

Paigen2:6	Paigen2	lipid profile	high-fat diet	total cholesterol (plasma) [mg/dL] CHOL 9906 baseline after 17wks on diet Δchange	inbred w/CC7	42	both	7-9wks	N=9	2002

Paigen2:21	Paigen2	lipid profile	high-fat diet	triglycerides (plasma, 4h fast) [mg/dL] TG 9921 baseline after 17wks on diet Δchange	inbred w/CC7	42	both	7-9wks	N=9	2002

Paigen3:5	Paigen3	body weight	high-fat diet	body weight [g] bw 2805 start after 8wks on diet fold change	obesity mutants	8	both	7-11wks	N=25	2000

Tarantino1:2	Tarantino1	open field test	cocaine	distance traveled, 30 min test [cm] dist 45911 baseline (day 2) treated (day 3) difference	inbred	45	m	8-11wks	N=18	2015

Tarantino1:5	Tarantino1	open field test	cocaine	ambulatory episodes, 30 min test [n] amb_epi 45916 baseline (day 2) treated (day 3) difference	inbred	45	m	8-11wks	N=18	2015

Tarantino1:8	Tarantino1	open field test	cocaine	rearing episodes, 30 min test [n] rear 45921 baseline (day 2) treated (day 3) difference	inbred	45	m	8-11wks	N=18	2015

Tarantino1:11	Tarantino1	open field test	cocaine	average velocity, 30 min test [cm/s] vel 45926 baseline (day 2) treated (day 3) difference	inbred	45	m	8-11wks	N=18	2015

Tarantino1:14	Tarantino1	open field test	cocaine	percentage of time resting, 30 min test [%] rest 45931 baseline (day 2) treated (day 3) difference	inbred	45	m	8-11wks	N=18	2015

Xenakis2:161	Xenakis2	body weight	arsenic	body weight [g] bw 118315 iAs: 4 wks before 0 wks after 2 wks after 4 wks after 8 wks after 16 wks after (3 more)...	DO population		m	4-34wks	N=74	2022

Xenakis2:170	Xenakis2	MRI	arsenic	body weight measured by MRI [g] bw_mri 118324 iAs: 2 wks before 12 wks after 24 wks after	DO population		m	6-32wks	N=74	2022

Xenakis2:173	Xenakis2	intake monitoring	arsenic	food consumption [g] food 118327 iAs: 4 wks before to start start to 2 wks after 2 to 4 wks after 4 to 8 wks after (4 more)...	DO population		m	4-34wks	N=74	2022

Xenakis2:200	Xenakis2	MRI	arsenic	percent of body mass that is fat [%] fat_pct 118354 iAs: 2 wks before 12 wks before 24 wks after	DO population		m	6-32wks	N=74	2022

Xenakis2:203	Xenakis2	MRI	arsenic	weight of lean tissue [g] lean_wt 118357 iAs: 2 wks before 12 wks after 24 wks after	DO population		m	6-32wks	N=74	2022

Xenakis2:206	Xenakis2	MRI	arsenic	percent of body mass that is lean [%] lean_pct 118360 iAs: 2 wks before 12 wks after 24 wks before	DO population		m	6-32wks	N=74	2022

Xenakis2:216	Xenakis2	metabolic panel	arsenic	fasting blood glucose (6h fast) [mg/dL] FBG 118370 iAs: 1 wk before 4 wks after 8 wks after 13 wks after 16 wks after 20 wks after 25 wks after	DO population		m	7-33wks	N=74	2022

Xenakis2:223	Xenakis2	metabolic panel	arsenic	blood glucose, 15 min after intraperitoneal (i.p. 0.2% glucose, 6h fast) injection [mg/dL] BG15 118377 iAs: 1 wk before 13 wks after 25 wks after	DO population		m	7-33wks	N=74	2022

Xenakis2:226	Xenakis2	hormone quantification	arsenic	fasting plasma insulin (6h fast) [ng/mL] FPI 118380 iAs: 1 wk before 4 wks after 8 wks after 13 wks after 16 wks after 20 wks after 25 wks after	DO population		m	7-33wks	N=71	2022

Xenakis2:233	Xenakis2	hormone quantification	arsenic	plasma insulin, 15 min after intraperitoneal (i.p. 0.2% glucose, 6h fast) injection [ng/mL] PI15 118387 iAs: 1 wk before 13 wks after 25 wks after	DO population		m	7-33wks	N=72	2022

Xenakis2:236	Xenakis2	hormone quantification	arsenic	fasting plasma insulin (6h fast), coefficient of variation (CV) [%] FPI_CV 118390 iAs: 1wk before 4 wks after 8 wks after 13 wks after 16 wks after 20 wks after 25 wks after	DO population		m	7-33wks	N=73	2022

Xenakis2:243	Xenakis2	hormone quantification	arsenic	plasma insulin, 15 min after intraperitoneal (i.p. 0.2% glucose, 6h fast) injection, coefficient of variation (CV) [%] PI15_CV 118397 iAs: 1wk before 13 wks after 25 wks after	DO population		m	7-33wks	N=72	2022

Albers1

lipid profile

high-fat diet

total cholesterol (plasma CHOL) [mmol/L] chol 1901 baseline after 6wks on diet Δchange

inbred

15

both

6-8wks

N=8

1999

Albers1

lipid profile

high-fat diet

HDL cholesterol (plasma HDL) [mmol/L] HDLC 1902 baseline after 6wks on diet Δchange

inbred

15

both

6-8wks

N=8

1999

Albers1

lipid profile

high-fat diet

non-HDL cholesterol (plasma non-HDL) [mmol/L] nonHDLC 1903 baseline after 6wks on diet Δchange

inbred

15

both

6-8wks

N=8

1999

Albers1

lipid profile

high-fat diet

total phospholipid (plasma) [mmol/L] PL 1910 baseline after 6wks on diet Δchange

inbred

15

both

6-8wks

N=8

1999

Albers1

lipid profile

high-fat diet

HDL phospholipid (plasma) [mmol/L] PL_HDL 1911 baseline after 6wks on diet Δchange

inbred

15

both

6-8wks

N=8

1999

Albers1

lipid profile

high-fat diet

non-HDL phospholipid (plasma) [mmol/L] PL_nonHDL 1912 baseline after 6wks on diet Δchange

inbred

15

both

6-8wks

N=8

1999

Albers1

protein activity assessment

high-fat diet

phospholipid transfer protein activity (plasma) [µmol/mL/h] PLTP 1913 baseline after 6wks on diet Δchange

inbred

15

both

6-8wks

N=8

1999

Albers1

lipid profile

high-fat diet

percentage of large HDL particles (10-13 nm) (plasma) [%] largeHDL 1922 baseline after 6wks on diet Δchange

inbred

15

both

6-8wks

N=8

1999

Albers1

lipid profile

high-fat diet

HDL peak size (plasma) [nm] HDLsize 1923 baseline after 6wks on diet Δchange

inbred

15

both

6-8wks

N=8

1999

Albers1

lipid profile

high-fat diet

triglycerides (plasma TG) (4h fast) [mmol/L] TG 1928 baseline after 6wks on diet Δchange

inbred

15

both

6-8wks

N=8

1999

Crabbe3

rotarod

ethanol

latency to-fall, accelerating rotarod, test day 1 20 rpm/min (ARR1) [s] ARR1_20rpm 15840 baseline ethanol difference

inbred

8

both

9-17wks

N=6

2003

Crabbe3

rotarod

ethanol

latency to-fall, accelerating rotarod, test day 2 30 rpm/min (ARR1) [s] ARR1_30rpm 15845 baseline ethanol difference

inbred

8

both

9-17wks

N=6

2003

Crabbe3

rotarod

ethanol

latency to fall, accelerating rotarod, 20 rpm/min (ARR2) [s] ARR2_20rpm 15855 baseline ethanol

inbred

21

both

9-17wks

N=9

2003

Crabbe4

grip strength

ethanol

grip strength test: peak force applied [g] grip 19106 baseline 30min after ethanol

inbred

21

both

7-12wks

N=6

2003

Gershenfeld1

tail suspension test

imipramine

TST duration of immobility, treatment group, 6 min test [s] TST_Rx 16203 baseline imipramine 30mg/kg

inbred

12

m

5-10wks

N=5

2003

Mathes1

body weight

exercise

body weight [g] bw 45201 before exercise after exercise difference

CC pre w/par

184

m

10-12wks

N=1

2011

Mathes1

MRI

exercise

percent fat, whole body with head [%] pct_fat 45204 before exercise after exercise difference

CC pre w/par

184

m

10-12wks

N=1

2011

Mathes1

intake monitoring

exercise

caloric intake [kcal/d] calories 45207 before exercise during exercise

CC pre w/par

183

m

10-12wks

N=1

2011

Nadeau1

body weight

high-fat diet

body weight [g] bw 28301 baseline after 12wks on diet Δchange

B6.A consomic w/par

24

m

5wks

N=18

2008

Nadeau2

body size and weight

high-fat high-sucrose diet

body weight [g] bw 53001 baseline after 16wks on diet weight gain

B6.A consomic w/par

24

m

5wks

N=39

2015

Naggert1

metabolic panel

high-fat diet

glucose (plasma GLU, 4h fast) [mg/dL] GLU 14302 baseline after 17wks on diet Δchange

inbred w/CC7

43

both

7-9wks

N=10

2003

Paigen1

body weight

high-fat diet

body weight [g] bw 2905 start after 8wks on diet fold change

inbred

43

both

7-11wks

N=12

2000

Paigen2

lipid profile

high-fat diet

HDL cholesterol (plasma) [mg/dL] HDLC 9904 baseline after 17wks on diet Δchange

inbred w/CC7

42

both

7-9wks

N=9

2002

Paigen2

lipid profile

high-fat diet

non-HDL cholesterol (plasma) [mg/dL] nonHDL 9905 baseline after 17wks on diet Δchange

inbred w/CC7

42

both

7-9wks

N=9

2002

Paigen2

lipid profile

high-fat diet

total cholesterol (plasma) [mg/dL] CHOL 9906 baseline after 17wks on diet Δchange

inbred w/CC7

42

both

7-9wks

N=9

2002

Paigen2

lipid profile

high-fat diet

triglycerides (plasma, 4h fast) [mg/dL] TG 9921 baseline after 17wks on diet Δchange

inbred w/CC7

42

both

7-9wks

N=9

2002

Paigen3

body weight

high-fat diet

body weight [g] bw 2805 start after 8wks on diet fold change

obesity mutants

8

both

7-11wks

N=25

2000

Tarantino1

open field test

cocaine

distance traveled, 30 min test [cm] dist 45911 baseline (day 2) treated (day 3) difference

inbred

45

m

8-11wks

N=18

2015

Tarantino1

open field test

cocaine

ambulatory episodes, 30 min test [n] amb_epi 45916 baseline (day 2) treated (day 3) difference

inbred

45

m

8-11wks

N=18

2015

Tarantino1

open field test

cocaine

rearing episodes, 30 min test [n] rear 45921 baseline (day 2) treated (day 3) difference

inbred

45

m

8-11wks

N=18

2015

Tarantino1

open field test

cocaine

average velocity, 30 min test [cm/s] vel 45926 baseline (day 2) treated (day 3) difference

inbred

45

m

8-11wks

N=18

2015

Tarantino1

open field test

cocaine

percentage of time resting, 30 min test [%] rest 45931 baseline (day 2) treated (day 3) difference

inbred

45

m

8-11wks

N=18

2015

Xenakis2

body weight

arsenic

body weight [g] bw 118315 iAs: 4 wks before 0 wks after 2 wks after 4 wks after 8 wks after 16 wks after (3 more)...

DO population

m

4-34wks

N=74

2022

Xenakis2

MRI

arsenic

body weight measured by MRI [g] bw_mri 118324 iAs: 2 wks before 12 wks after 24 wks after

DO population

m

6-32wks

N=74

2022

Xenakis2

intake monitoring

arsenic

food consumption [g] food 118327 iAs: 4 wks before to start start to 2 wks after 2 to 4 wks after 4 to 8 wks after (4 more)...

DO population

m

4-34wks

N=74

2022

Xenakis2

MRI

arsenic

percent of body mass that is fat [%] fat_pct 118354 iAs: 2 wks before 12 wks before 24 wks after

DO population

m

6-32wks

N=74

2022

Xenakis2

MRI

arsenic

weight of lean tissue [g] lean_wt 118357 iAs: 2 wks before 12 wks after 24 wks after

DO population

m

6-32wks

N=74

2022

Xenakis2

MRI

arsenic

percent of body mass that is lean [%] lean_pct 118360 iAs: 2 wks before 12 wks after 24 wks before

DO population

m

6-32wks

N=74

2022

Xenakis2

metabolic panel

arsenic

fasting blood glucose (6h fast) [mg/dL] FBG 118370 iAs: 1 wk before 4 wks after 8 wks after 13 wks after 16 wks after 20 wks after 25 wks after

DO population

m

7-33wks

N=74

2022

Xenakis2

metabolic panel

arsenic

blood glucose, 15 min after intraperitoneal (i.p. 0.2% glucose, 6h fast) injection [mg/dL] BG15 118377 iAs: 1 wk before 13 wks after 25 wks after

DO population

m

7-33wks

N=74

2022

Xenakis2

hormone quantification

arsenic

fasting plasma insulin (6h fast) [ng/mL] FPI 118380 iAs: 1 wk before 4 wks after 8 wks after 13 wks after 16 wks after 20 wks after 25 wks after

DO population

m

7-33wks

N=71

2022

Xenakis2

hormone quantification

arsenic

plasma insulin, 15 min after intraperitoneal (i.p. 0.2% glucose, 6h fast) injection [ng/mL] PI15 118387 iAs: 1 wk before 13 wks after 25 wks after

DO population

m

7-33wks

N=72

2022

Xenakis2

hormone quantification

arsenic

fasting plasma insulin (6h fast), coefficient of variation (CV) [%] FPI_CV 118390 iAs: 1wk before 4 wks after 8 wks after 13 wks after 16 wks after 20 wks after 25 wks after

DO population

m

7-33wks

N=73

2022

Xenakis2

hormone quantification

arsenic

plasma insulin, 15 min after intraperitoneal (i.p. 0.2% glucose, 6h fast) injection, coefficient of variation (CV) [%] PI15_CV 118397 iAs: 1wk before 13 wks after 25 wks after

DO population

m

7-33wks

N=72

2022

Study designs: all MPD measure sets of study design type basetrt

Filter Table Results